ICD-10 Coding for Screening PSA(R97.20, R97.20B, R97.20E)
Learn about the ICD-10 code Z12.5 for screening PSA, including documentation requirements, coding pitfalls, and billing considerations.
Complete code families applicable to Screening PSA
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| Z12.5 | Encounter for screening for malignant neoplasm of prostate | Use for asymptomatic patients undergoing routine prostate cancer screening. |
|
| R97.20 | Elevated prostate specific antigen [PSA] | Use when PSA levels are elevated and the patient is asymptomatic. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutScreening PSA
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Screening PSA.
Omitting family history in documentation
Impact
Clinical: Incomplete patient history, Regulatory: Potential audit risk, Financial: Possible claim denial
Mitigation
Always ask about family history, Document any relevant family history
Using Z12.5 for symptomatic patients
Impact
Reimbursement: Claims may be denied if symptoms are present., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate patient records.
Mitigation
Use appropriate codes for symptoms and elevated PSA.
Incorrect use of screening codes
Impact
Using Z12.5 for patients with symptoms
Mitigation
Verify patient symptoms before coding